Invivyd : J.P. Morgan 41st Annual Healthcare Conference

J.P. Morgan 41st Annual Healthcare Conference

January 2023

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, the future of the COVID-19 landscape including the expectation of continued evolution and emergence of new variants and subvariants; our ongoing research and clinical development plans; the timing, progress and results of our preclinical studies and clinical trials of our product candidates; the initiation, modification and completion of studies or trials and related preparatory work; the period during which the results of our clinical trials and other studies and research activities will become available, and our research and development programs; our ability to identify novel antibodies designed to address the evolving SARS-CoV-2 threat; our ability to obtain and maintain regulatory approvals for our product candidates; our expectations regarding the size of the patient populations, market acceptance and opportunity for and clinical utility of our product candidates, if approved for commercial use; our expectations regarding the scope of any approved indication for our product candidates; our ability to successfully commercialize our product candidates, including for a new drug category; our ability to leverage our platform to identify and develop future product candidates in additional areas of need; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; the anticipation of ongoing discussions with health authorities; the potential for an emergency use authorization in the U.S. or other regulatory approval; our preclinical activity, plans, technology and resources to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza, in the U.S. and globally; our belief in the potential to discover and develop pipeline candidates as potent and durable antibodies or combination of antibodies for COVID-19; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business and those of our collaborators, our clinical trials and our financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of our product candidates or combination of candidates based on neutralizing activity in pre-clinical studies; variability of results in models used to predict activity against SARS-CoV-2 variants of concern; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our clinical trials; whether we are able to successfully monitor, analyze, engineer and optimize new product candidates; whether we are able to create a flow of product candidates that address virus evolution; whether our product candidates or combination of candidates are able to demonstrate activity against predominant SARS-CoV-2 variant(s) in the U.S. and globally; whether we are able to successfully submit an emergency use authorization in the future, and the outcome of any such emergency use authorization submission; whether research and development efforts will improve efficacy of our product candidates against predominant variants or identify additional monoclonal antibodies or combination of antibodies for the prevention and treatment of COVID-19 and other infectious diseases; whether research and development efforts will identify and result in safe and effective therapeutic or preventative options for other infectious diseases in the U.S. or globally and whether we have adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and our most recent Quarterly Report on Form 10-Q, each filed with the Securities and Exchange Commission (the "SEC"), and in our other filings with the SEC, and in our future reports to be filed with the SEC and available at www.sec.gov. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this presentation are made as of this date, and we undertake no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

© 2023 Invivyd, Inc., Invivyd and the Invivyd logo are trademarks of Invivyd, Inc.

1

OVERVIEW OF INVIVYD

OUR	DISCOVERY	LEAD PROGRAM	APPLICATION IN VIRAL
FOCUS	PLATFORM		DISEASES

• Antibodies designed to protect humanity from serious viral diseases
• Initial focus on COVID-19 with antibodies designed towards addressing variants of concern

• Rapid antibody isolation, engineering, and predictive modeling of viral evolution
• Identification and engineering of antibodies across multiple dimensions such as potency, durability, half-life, potential to resist escape, and manufacturability

• NVD200 for COVID-19; a combination monoclonal antibody product
• Phase 1 trial start planned for Q1 2023

• Growing number of antibodies aiming to overcome the challenges of viral evolution, starting in COVID-19
• Plans to expand into other respiratory viruses with ongoing preclinical activity in influenza

3

INVIVYD IN ACTION: APPROACH TO SELECTION OF NEXT GENERATION COVID-19 PRODUCT CANDIDATES

Continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat

~10 million B Cells

Mine human antibody repertoires induced following
contemporary SARS-CoV-2 exposures	667 RBD binders

Pinpoint dominant spike protein sites targeted by human antibody repertoires and map common mutational escape routes to predict future variants

Identify potent mAb candidates that target rare epitopes

not under strong immune pressure

311 neutralizers

171 non-convergent clones 60 high potency

31 broad VOC binders

6 low risk escape

NVD200 + Other

Candidates

10

NVD200: A COMBINATION APPROACH OF TWO ANTIBODIES TARGETING DISTINCT EPITOPES

NVD200 = VYD224 + VYD222 (Re-engineered ADG20)

• Designed for:	VYD224
•	High potency	VYD222
•	Lack of polyreactivity

• • Long half-life
  • Developability
  • Patient and health system ease of use
  • Potential to resist escape
  • • Target non-overlapping epitopes of spike RBD
    • Rare epitopes under less immune pressure
    • Conserved across human ACE2-using sarbecoviruses
• NVD200 shows in vitro neutralizing activity against: Pre-Omicron VOCs, Omicron variants BA.1, BA.2, BA.4, BA4.6 BA.5, BA.2.75, and SARS-CoV-2.
• Phase 1 trial start planned Q1 2023

RBD, receptor binding domain

VOC, variant of concern

11